Imunon, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Stacy R. Lindborg
- Full Time Employees
- 25
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 997 Lenox Drive Lawrenceville NJ United States of America 08648
- IPO Date
- Mar 1, 1999
- CIK
- 0000749647
- Website
- imunon.com
- Similar Companies
- Business
- Imunon, Inc. is a clinical-stage biotechnology company focused on developing DNA-based immunotherapies and vaccines primarily targeting difficult-to-treat cancers and infectious diseases. The company's main products include IMNN-001, a DNA-based immunotherapy in Phase II clinical development for the localized treatment of advanced ovarian cancer, leveraging interleukin-12 to stimulate immune response; IMNN-101, a COVID-19 booster vaccine candidate; IMNN-102, aimed at treating Lassa virus infections; and IMNN-201, a Trp2 tumor-associated antigen vaccine for melanoma in preclinical stages. Imunon also develops broader non-viral DNA technology platforms, including TheraPlas for protein and cytokine coding in solid tumor treatment and PlaCCine for encoding viral antigens to induce strong immune responses. The company manages the full drug development process in-house, comprising bench discovery, active ingredient manufacture, formulation, testing, and clinical production, enhancing flexibility and control. Founded in 1982 and headquartered in Lawrenceville, New Jersey, Imunon operates primarily in the biotechnology sector within healthcare, focusing on immuno-oncology and infectious disease vaccine markets. A significant recent corporate change includes its rebranding from Celsion Corporation to Imunon, Inc. in September 2022, reflecting a strategic pivot towards DNA-based immunotherapies. In 2024 and 2025, the company advanced its key program IMNN-001 to Phase III clinical trials after successful Phase II results demonstrating an 11.1-month median overall survival improvement in ovarian cancer patients. Imunon completed a $10 million registered direct offering in mid-2024 to strengthen its financial position and has conducted a 15% stock dividend to support shareholder value. The company faces Nasdaq compliance challenges but remains focused on expanding its pipeline and commercial development with ongoing research and preclinical programs, including personalized cancer vaccines based on its IndiPlas platform. Imunon's product pipeline and platform technologies position it in the immunotherapy market addressing oncology and viral diseases, emphasizing localized and personalized treatment approaches with proprietary plasmid DNA delivery systems. Its lead clinical asset IMNN-001 and multiple preclinical candidates underline a robust R&D focus, supported by internal manufacturing and quality control capabilities, enabling a vertically integrated development model within its U.S. operations. The company maintains collaborations and investments to advance its therapeutic modalities while navigating capital markets to fund ongoing clinical trials and operational growth. Overall, Imunon, Inc. integrates innovative DNA plasmid technology with immunology to develop transformative medicines for cancer and infectious diseases, operating out of Lawrenceville with a clear path toward late-stage clinical development and commercial readiness. The company's recent financial maneuvers, trial progressions, and pipeline expansions reflect strategic efforts to establish leadership in its niche biotechnology segment.
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
Imunon, Inc. (IMNN) Q4 2025 Earnings Call Transcript
IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
Imunon (IMNN) Projected to Post Quarterly Earnings on Thursday
Head-To-Head Analysis: Pharma Mar (OTCMKTS:PHMMF) vs. Imunon (NASDAQ:IMNN)
IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
Head to Head Review: Allogene Therapeutics (NASDAQ:ALLO) and Imunon (NASDAQ:IMNN)
Imunon, Inc. (NASDAQ:IMNN) Receives $232.50 Average Price Target from Analysts
IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
Imunon (NASDAQ:IMNN) Stock Price Up 5.3% – Should You Buy?
Imunon, Inc. (IMNN) Q3 2025 Earnings Call Transcript
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
Imunon, Inc. (IMNN) Discusses IMNN-001 Immunotherapy Progress and Milestones in OVATION 3 Ovarian Cancer Study Transcript
IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer